-
Tytuł:
-
High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
-
Autorzy:
-
Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Wirtz RM; STRATIFYER Molecular Pathology GmbH, 541713 Cologne, Germany.
Breyer J; Caritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
Eckstein M; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Weyerer V; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Kubon J; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Erben P; Department of Urology and Urosurgery, University Medical Centre Mannheim, 68167 Mannheim, Germany.; Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Bolenz C; Department of Urology and Pediatric Urology, University Hospital Ulm, 89081 Ulm, Germany.
Burger M; Caritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
Hartmann A; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Wach S; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Keck B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
-
Źródło:
-
Life (Basel, Switzerland) [Life (Basel)] 2021 Jun 30; Vol. 11 (7). Date of Electronic Publication: 2021 Jun 30.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Basel, Switzerland : MDPI AG, 2011-
-
References:
-
Bladder Cancer. 2016 Jan 7;2(1):37-47. (PMID: 27376123)
Eur Urol. 2017 Mar;71(3):447-461. (PMID: 27324428)
Jpn J Clin Oncol. 2012 Jul;42(7):569-77. (PMID: 22593639)
Cancer Res. 2013 Oct 1;73(19):5914-25. (PMID: 23928991)
BMC Cancer. 2019 Apr 8;19(1):331. (PMID: 30961575)
Eur Urol. 2020 Apr;77(4):420-433. (PMID: 31563503)
Urol J. 2014 Nov 30;11(6):1968-73. (PMID: 25433476)
Nat Protoc. 2008;3(6):1101-8. (PMID: 18546601)
Mol Cell Endocrinol. 2018 Apr 15;465:73-81. (PMID: 28652170)
Transl Oncol. 2019 Apr;12(4):661-668. (PMID: 30831560)
Eur Urol. 1997;31(3):360-4. (PMID: 9129932)
Urol Int. 2020;104(9-10):810-823. (PMID: 32460292)
World J Urol. 2021 May;39(5):1549-1558. (PMID: 32676741)
Lancet Diabetes Endocrinol. 2018 Aug;6(8):647-658. (PMID: 30017799)
Urology. 2004 Aug;64(2):383-8. (PMID: 15302512)
Histol Histopathol. 2020 May;35(5):423-432. (PMID: 31803932)
Transl Oncol. 2017 Jun;10(3):340-345. (PMID: 28342317)
BJU Int. 2011 Jul;108(1):24-30. (PMID: 21070579)
Mol Carcinog. 2011 Dec;50(12):931-44. (PMID: 21400613)
Oncotarget. 2016 Mar 22;7(12):14153-60. (PMID: 26885620)
Pathol Oncol Res. 2019 Jul;25(3):987-994. (PMID: 29862474)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Eur Urol. 2014 Jan;65(1):69-76. (PMID: 23910233)
Eur Urol. 2012 Apr;61(4):845-6. (PMID: 22373879)
Virchows Arch. 2017 Mar;470(3):267-274. (PMID: 28074276)
Oncotarget. 2015 Jun 10;6(16):14710-9. (PMID: 25900243)
Cancer Res. 2010 May 1;70(9):3463-72. (PMID: 20406976)
Int J Mol Sci. 2018 Oct 30;19(11):. (PMID: 30380731)
Eur Urol. 2016 Feb;69(2):300-10. (PMID: 26346676)
Endocr Relat Cancer. 2020 Apr;27(4):231-244. (PMID: 32031965)
Nat Rev Urol. 2016 Oct;13(10):570-1. (PMID: 27578042)
Endocr Relat Cancer. 2015 Oct;22(5):R265-77. (PMID: 26229034)
BJU Int. 2011 Feb;107(4):540-6. (PMID: 21276177)
J Urol. 2012 Jul;188(1):276-86. (PMID: 22608749)
Eur Urol. 2013 Feb;63(2):234-41. (PMID: 22877502)
Oncotarget. 2018 Feb 19;9(19):15001-15014. (PMID: 29599921)
Eur Urol. 2021 Apr;79(4):480-488. (PMID: 33419683)
Mol Carcinog. 2013 Feb;52(2):94-102. (PMID: 22086872)
Clin Cancer Res. 2019 Apr 15;25(8):2450-2457. (PMID: 30573691)
J Urol. 2017 Feb;197(2):308-313. (PMID: 27506696)
Am J Transl Res. 2016 Feb 15;8(2):578-87. (PMID: 27158349)
Virchows Arch. 2016 Nov;469(5):547-552. (PMID: 27514658)
Cancer Discov. 2013 Nov;3(11):1254-71. (PMID: 24027197)
Urol Oncol. 2011 Jan-Feb;29(1):43-51. (PMID: 19372057)
Oncotarget. 2014 Dec 30;5(24):12665-74. (PMID: 25557268)
Am J Pathol. 2013 May;182(5):1811-20. (PMID: 23499463)
Eur Urol Focus. 2018 Jul;4(4):586-590. (PMID: 28753845)
Mol Cancer Ther. 2015 Nov;14(11):2586-94. (PMID: 26264279)
Int Urol Nephrol. 2015 Jan;47(1):81-5. (PMID: 25218615)
Yonsei Med J. 2014 Sep;55(5):1214-21. (PMID: 25048477)
Cancers (Basel). 2017 Feb 22;9(2):. (PMID: 28241422)
J Natl Cancer Inst. 2007 Apr 4;99(7):558-68. (PMID: 17406000)
Endocr Relat Cancer. 2011 Jul 04;18(4):451-64. (PMID: 21613411)
-
Grant Information:
-
ELAN 18-08-18-1-Sikic Friedrich-Alexander-Universität Erlangen-Nürnberg
-
Contributed Indexing:
-
Keywords: KRT20; KRT5; NMIBC; PCR; androgen receptor; bladder cancer; mRNA
-
Entry Date(s):
-
Date Created: 20210702 Latest Revision: 20210727
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8306811
-
DOI:
-
10.3390/life11070642
-
PMID:
-
34209360
-
The role of the androgen receptor (AR) in non-muscle-invasive bladder cancer (NMIBC) remains controversial. We retrospectively analyzed the mRNA expression of AR using RT-qPCR in 95 patients with high-risk NMIBC treated with a bladder-sparing approach and correlated AR with clinical data and recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). The mRNA expression of AR and KRT5, i.e., the basal-like subtype, was strongly correlated (rs = 0.456; p < 0.001). AR ( p = 0.053) and KRT5 ( p = 0.029) mRNA expression was negatively correlated with tumor grade. Kaplan-Meier analyses indicated significantly prolonged CSS ( p = 0.020) and OS ( p = 0.015) and a trend towards longer RFS ( p = 0.051) in patients with high AR expression. High KRT5 expression was associated with significantly longer RFS ( p = 0.033), CSS ( p = 0.029) and OS ( p = 0.030), while high KRT20 expression was associated with reduced RFS ( p = 0.042). In multivariable analysis, none of the molecular markers was an independent prognostic factor. When performing a substratification with regard to molecular markers and clinicopathological parameters, high AR expression showed improved OS in patients with high KRT20 mRNA expression ( p = 0.041). Women showed significantly longer OS in cases with high AR expression ( p = 0.011). High AR was associated with significantly improved CSS in males ( p = 0.044) and patients with instillation therapy ( p = 0.040), while OS was improved regardless of instillation therapy. Younger patients with high AR expression had significantly improved RFS ( p = 0.021), CSS ( p = 0.014) and OS ( p = 0.007). RFS was also improved in patients with high AR and low expression of either KRT5 ( p = 0.003) or KRT20 ( p = 0.014), but not in patients with high expression of KRT5 or KRT20. In conclusion, high AR mRNA expression is correlated with KRT5 mRNA expression and is associated with an improved outcome in high-risk NMIBC.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.